WellPATH-PREVENT:针对因自杀意念或企图而住院的中老年人的移动干预
The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
研究概览
详细说明
R61 Phase: In this "proof-of-concept" phase, interventionists will administer 12 weeks of WellPATH-PREVENT in 40 middle-aged and older adults who have been discharged after being hospitalized for suicidal ideation or suicide attempt. The interventionist will help the patient incorporate the appropriate data (i.e., triggers, negative emotions, cognitive reappraisal techniques) into the tablet, train the patients on how to use the tablet, and coach them during the 12 weeks. There will be 4 assessments: At study entry (admission/during hospitalization), hospital discharge, 6, and 12 weeks. An EEG will be conducted upon entry into the study, at Week 6, and at Week 12.
R33 Phase: 75 middle-aged and older adults who have been recently discharged after a hospitalization for suicidal ideation or attempt will be recruited and randomized to an optimized version of WellPATH-PREVENT (Week 6 and Week 12 duration based on R61 results) or to Attention Control-Usual Care with a tablet (AC-UC). There will be 5 assessments: At study entry (admission/during hospitalization), discharge, 6, 12 and 24 weeks. Participants who exit the study prior to completion will be invited to have an assessment before termination as close to the scheduled time point as possible. Psychiatrically re-hospitalized participants will not be dropped from the study but will have an additional assessment and will continue the assessments as scheduled based on their initial hospitalization.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Dimitris Kiosses, PhD
- 电话号码:914-997-4381
- 邮箱:dkiosses@med.cornell.edu
研究联系人备份
- 姓名:Laurie Evans, MS
- 电话号码:1012570 914-682-9100
- 邮箱:lad9011@med.cornell.edu
学习地点
-
-
New York
-
New York、New York、美国、10065
- 尚未招聘
- New York Presbyterian Hospital/Weill Cornell Medicine
-
接触:
- Dimitris Kiosses, PhD
- 电话号码:914-997-4381
- 邮箱:dkiosses@med.cornell.edu
-
接触:
- Laurie Evans, MS
- 电话号码:1012570 914-682-9100
- 邮箱:lad9011@med.cornell.edu
-
White Plains、New York、美国、10605
- 招聘中
- Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine
-
接触:
- Dimitris Kiosses, PhD
- 电话号码:914-997-4381
- 邮箱:dkiosses@med.cornell.edu
-
接触:
- Laurie Evans, MS
- 电话号码:1012570 914-682-9100
- 邮箱:lad9011@med.cornell.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 50-90 years old
- Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia
- Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts."
- We will also include patients on psychotropics and on after-care community psychotherapy.
Exclusion Criteria:
- Current diagnosis of Psychotic Disorders; Diagnosis of Dementia
- Cognitive Impairment (MMSE ≤ 24)
- Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry
- Aphasia, sensory problems, and/or inability to speak English.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:概念验证 WellPATH-PREVENT (R61)
|
WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app. |
|
实验性的:优化 WellPATH-PREVENT (R33)
|
The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal. |
|
无干预:Attention Control Usual Care (R33)
The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61
大体时间:Study Entry, Week 6, Week 12
|
ERP is used to measure the amplitude (magnitude) of electrocortical activity (measured in μV) during an emotion regulation task. |
Study Entry, Week 6, Week 12
|
|
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R33
大体时间:Study Entry, Week 6, Week 12, Week 24
|
ERP is used to measure the amplitude (magnitude) of electrocortical activity (measured in μV) during an emotion regulation task. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Self-Reported Affect - R61
大体时间:Study Entry, Week 6, Week 12
|
Self-reported affect is used to study changes in negative emotions during an EEG emotion regulation task. It is based on a participant's rating of negative emotions (Likert scale: 1-5; 5 most negative) during the task. |
Study Entry, Week 6, Week 12
|
|
Change in Self-Reported Affect - R33
大体时间:Study Entry, Week 6, Week 12, Week 24
|
Self-reported affect is used to study changes in negative emotions during an EEG emotion regulation task. It is based on a participant's rating of negative emotions (Likert scale: 1-5; 5 most negative) during the task. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R61
大体时间:Study Entry, Week 6, Week 12
|
ERQ is an interviewer-administered instrument to evaluate cognitive reappraisal ability. Scores can range from 1-7, where higher scores indicate greater use of emotion regulation strategies and lower scores indicate less frequent use of such strategies. |
Study Entry, Week 6, Week 12
|
|
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33
大体时间:Study Entry, Week 6, Week 12, Week 24
|
ERQ is an interviewer-administered instrument to evaluate cognitive reappraisal ability. Scores can range from 1-7, where higher scores indicate greater use of emotion regulation strategies and lower scores indicate less frequent use of such strategies. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Client Satisfaction with Treatment (CSQ) - R61
大体时间:Week 6, Week 12
|
Client Satisfaction Questionnaire is a self-report that measures patient satisfaction with intervention/treatment. Scores can range from 3-12, where higher values indicate higher satisfaction. |
Week 6, Week 12
|
|
Change in Client Satisfaction with Treatment (CSQ) - R33
大体时间:Week 6, Week 12, Week 24
|
Client Satisfaction Questionnaire is a self-report that measures patient satisfaction with intervention/treatment. Scores can range from 3-12, where higher values indicate higher satisfaction. |
Week 6, Week 12, Week 24
|
|
Change in Suicide Risk - Columbia Suicide Severity Scale (C-SSRS) - R61
大体时间:Weekly from Study Entry to Week 12 (R61)
|
C-SSRS is used to measure intensity of suicidal ideation. Scores range from 0-5, where higher scores indicate more severe ideation. |
Weekly from Study Entry to Week 12 (R61)
|
|
Change in Suicide Risk - Columbia Suicide Severity Scale (C-SSRS) - R33
大体时间:Weekly from Study Entry to Week 24
|
C-SSRS is used to measure intensity of suicidal ideation. Scores range from 0-5, where higher scores indicate more severe ideation. |
Weekly from Study Entry to Week 24
|
合作者和调查者
调查人员
- 首席研究员:Dimitris Kiosses, PhD、Weill Medical College of Cornell University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 21-12024207
- R61MH128516 (美国 NIH 拨款/合同)
- R33MH128516 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified data from this study is submitted to the National Database for Clinical Trials related to Mental Illness (NDCT). The NDCT is run by NIH and allows researchers studying mental health to collect and share information with each other. Researchers must apply to NIH in order to be allowed access to the data for 1 year's time; after which they must re-apply.
IPD 共享时间框架
Data will be available as per NIH's data sharing policy.
IPD 共享访问标准
Access criteria is determined by NIH and can be requested by applying online.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.